liminatuspharma.com (LIMN): Price-to-Projected Revenue Ratio

LIMN (Liminatus Pharma Inc.) - company brandmark

Liminatus Pharma generates revenue by implementing CAR-T technologies against solid tumors. The company is currently executing a plan to launch primary clinical trials and secure capital. The issuer's projected P/S ratio visualizes the trend of market expectations, where the current metric is 0.00. This ambitious biotech builds confidence through the development of unique antibodies for targeted immune activation.

LIMN Liminatus Pharma Inc.: Market Cap to Future Revenue Ratio in the range 05/02/2025 - 05/02/2025

Analytical breakdowns for Liminatus Pharma (LIMN)

- stock exchange capitalization data:
Summary company analysis:liminatuspharma.com LIMN
Manufactured products of Liminatus

To assess the financial stability of Liminatus Pharma (LIMN), it is critical to compare market capitalization with projected revenue, given the colossal costs associated with clinical trials and patent protection for immunotherapy. Analyzing forward P/S volatility through the company's P/S expectations allows for the determination of the balance between supply and demand, identifying risks of a sharp price correction in the absence of confirmed trading volumes.

Competitor analysis

ImmunityBio Inc - Forward Price-to-Revenue Multiple|Forward P/S Multiple Immunocore Corp IMCR|JANX - Price-to-Projected Revenue Ratio|RCUS (arcusbio.com) - Market Cap to Projected Revenue|Zymeworks Biopharmaceuticals (ZYME) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Tango Pharma (TNGX)|Forward Price-to-Revenue Multiple IOVA|IMTX - Projected Price to Revenue|Forward Price-to-Revenue Multiple XNCR (Xencor Corp)|Price to Expected Revenue Ratio CMPX|Forward P/S Multiple REPL (Replimune)|Forward Price to Sales LYEL|innate-pharma.com - Forward P/S Multiple|Market Cap to Future Revenue Ratio Pyxis Oncology|Compugen Limited (CGEN) - Price-to-Projected Revenue Ratio|IO Biotech, Inc. - Forward Price to Sales|STRO (sutrobio.com) - Forward P/S Multiple|Forward P/S Multiple MiNK Therapeutics Inc.|Price-to-Projected Revenue Ratio werewolftx.com (HOWL)|IMMX: Future Price to Revenue|alxoncology.com - Forward Price-to-Revenue Multiple|CUE - Forward Price-to-Revenue Multiple|PDSB - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Sonnet BioTherapeutics Holdings SONN|MAIA: Forward P/S Multiple|LAVA Therapeutics N.V. (LVTX) - Forward P/S Multiple|Forward Price-to-Revenue Multiple NXTC|Forward P/S Multiple leaptx.com|Forward P/S Multiple INTS|Market Cap to Expected Sales Ratio Sensei Biotherapeutics, Inc.|Forward P/S Multiple TOVX (Theriva Corp)|Market Cap to Expected Sales Ratio gritstonebio.com (GRTS)|kinetabio.com - Forward P/S Multiple|NexImmune (NEXI) - Forward Price-to-Revenue Multiple|turnstonebio.com (TSBX) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Vaccinex, Inc (VCNX)|Forward Price-to-Revenue Multiple HARP